Navigation Links
Maastricht University Medical Centre Advances Cranial Implant Technology with PEEK-OPTIMA
Date:6/2/2010

Maastricht University Medical Centre (MUMC+) has developed a novel cranio-maxillofacial implant technology that uses an advanced polymer biomaterial, PEEK-OPTIMA®, from Invibio Biomaterial Solutions. The polymer derived Patient Specific Implant (PSI) technology extends the range of patient/surgeon benefits beyond those of medical-grade titanium, the traditional biomaterial used for cranio-maxillofacial PSIs.

(PRWEB) June 2, 2010 -- Maastricht University Medical Centre (MUMC+) has developed a novel cranio-maxillofacial implant technology that uses an advanced polymer biomaterial, PEEK-OPTIMA®, from Invibio Biomaterial Solutions, to extend benefits to patients with severe malformation and defects of the skull and facial region. Patient-specific cranial implants are most commonly used to treat skull defects resulting from trauma, tumors and aneurysms.

The PEEK-OPTIMA® derived Patient Specific Implant (PSI) technology extends the range of patient/surgeon benefits beyond those of medical-grade titanium, the traditional biomaterial used for cranio-maxillofacial PSIs. The MUMC+ process uses CAD software to design the PSI to the individual cranio-maxillofacial contours of the patient. The customized implants are produced on-site, using a high speed milling fabrication process.

According to Maikel Beerens (B.Sc. in Medical Engineering), who initially designed and now markets IDEE’s (Instrument Development Engineering & Evaluation) patient specific implants (PSI), PEEK-OPTIMA’s material characteristics and performance properties provide real and valuable surgeon/patient benefits that include:

 
  • Ideal biological properties very comparable to bone;
  • No stress shielding;
  • No conductibility of temperature;
  • Separation of PEEK from surrounding bone, which ensures the initial position of the implant
  • Proven biocompatibility and biostability,
  • Natural radiolucency and compatibility with medical imaging to monitor site healing

“The patient’s own removed bone segments are always the first choice for implantation. However, unfortunately only a few of those re-implantations succeed, leaving the patient with a defect. To reconstruct this defect in the best way possible the surgeon uses a patient specific implant.

Although the use of PEEK is relatively new in the case of cranial implants, Invibio’s PEEK-OPTIMA® is proven with over 10 years of history in a wide variety of different regulatory approved devices. Their verified biocompatibility and biostability is crucial for surgeons when choosing materials”, commented Peter Kessler (chair professor, Department of Cranio-Maxillofacial Surgery, MUMC+).

The novel cranio-maxillofacial implant technology was co-developed by Maastricht University Medical Centre’s engineering department IDEE (Instrument Development Engineering & Evaluation), the Department of Cranio-Maxillofacial Surgery and Maastricht Instruments (MI).

About Invibio:
Invibio® is a global leader providing high performance biomaterials, advanced technical research and consultative solutions to medical device manufacturers across a wide range of markets. The company provides medical device manufacturers with PEEK-OPTIMA® polymer and compounds, MOTIS™ polymer, ENDOLIGN® composite and PEEK-CLASSIX™ polymer for the development of long- and short-term implantable medical devices.

For more information, please contact Invibio at: 866 468 4246 or +484 342 6004 (U.S.), +44 (0) 1253 898000 (U.K.), +852 2366 4448 (Asia Pacific) or online at www.invibio.com.

About IDEE:
IDEE (Instrument Development Engineering & Evaluation) is the engineering department of Maastricht University (UM). It provides services to the Faculty of Health, Medicine & Life Sciences (FHML) as well as the university hospital Maastricht (azM) together named MUMC+. IDEE develops innovative and unique medical devices to support academic, medical and industrial R&D focused on Life Sciences.

About Maastricht Instruments:
Maastricht Instruments BV (MI) is a high-tech solution provider within the medical field and life sciences as well as industrial related R&D. Located within the premises of the MUMC+ and working very closely with IDEE and the local medical researchers, MI has access to in-depth medical knowledge and experience. Based upon the medical know-how, combined with excellent competences of mechanical, electronic and software development, MI is able to realize creative proof of concept equipment & services and innovative “first of a kind” prototypes. Typical customers are researchers from universities, (academic) hospitals, medical centers, care institutes and industrial R&D institutes worldwide.
For more information, please contact MI at: Tel +31 (0) 43 3881371 or online at www.maastrichtinstruments.com, in the Patient Specific Implants section.

About the Maastricht University Medical Centre (MUMC+):
The Department of Cranio-Maxillofacial Surgery of the Maastricht University Medical Centre is specialized in cranio-maxillofacial reconstructions. The range of reconstructive procedures comprises also the reconstruction of large skull bone defects of various origins. Customized implants of various materials can be applied. The experience and close cooperation with the Department of Neurosurgery renders excellent functional and aesthetic results. The cooperation with IDEE guarantees safety, reliability and the of use state-of-the-art technologies. For more information visit MUMC+ at www.azm.nl.

###

Read the full story at http://www.prweb.com/releases/2010/06/prweb4074614.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. University of Minnesota, Mayo Clinic sign research pact with Karolinska
2. New research at the University of Leicester links shoplifting to your personality
3. University of Colorado Hospital Moving Forward with $400 Million Expansion
4. University Hospitals Neurological Institute earns Neuroscience Center of Excellence designation
5. Center for the Study of Aging established at University of Denver
6. University of Washington launches project to discover fundamentals of early learning
7. University of Washington Institute for Learning & Brain Sciences Launches Developing Mind Project
8. Water Enabled Technologies of Utah Signs MOU with Clemson University, South Carolina, for Water Desalination
9. Chicago Trial Attorney Inducted as Loyola University Chicago School of Law's First Cooney & Conway Chair in Advocacy
10. Life sciences research grants awarded through Inova Health System and George Mason University
11. FightSMA Awards $250,000 Grant to Gene Researcher at The Ohio State University
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Maastricht University Medical Centre Advances Cranial Implant Technology with PEEK-OPTIMA 
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology: